Ligand got its hands on the product through its 2023 buyout of Novan’s assets. Novan was originally trying to push Zelsuvmi over the FDA finish line, but the firm encountered setbacks in late ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

Predicting protein-ligand binding affinities is a critical problem in drug discovery and design. A majority of existing methods fail to accurately characterize and exploit the geometrically invariant ...

This indicates non-covalent ligand cobinding prevents the LBD from adopting a transcriptionally repressive helix 12 conformation within orthosteric pocket, explaining why non-covalent ligand cobinding ...

Ligand will make further payments based on commercial and regulatory milestones, with potential payments up to $28m by either 2030 or 2034 on QARZIBA royalties exceeding preset thresholds. The ...

This valuable study from Zaman et al. demonstrates that the cKit-Kit ligand complex is necessary for the formation and/or maintenance of molecular layer interneuron synapses in cerebellar Purkinje ...

We showcase the superiority of our approach by conducting extensive experiments and evaluations, including predicting protein-ligand binding affinity in the PBDBind v2020 dataset as well as the ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for ...

Ligand Pharmaceuticals was ready to spin off its antibody discovery wing into a new company when special purpose acquisition company Avista Public Acquisition Corp. came knocking. So now, a month ...

Neither Ligand, OmniAb, or APAC gives any assurance that Ligand, OmniAb or APAC will achieve their expectations. This caution is made under the safe harbor provisions of the Private Securities ...

Figure 1. Ligand-gated ion channel superfamily morphology. Shown is a near top-down view displaying preferred ligand and ion selectivity for P2-type ionotropic purinoreceptors (A), glutamate-gated ...